

Medication Assisted Treatment (MAT)

Nicholas Batson M.D.

History

- Early 1970's Methadone, 1984 Naltrexone approved, 2002 Buprenorphine approved

Opioid Use Disorder

- Loss of Control (amount, cravings, etc.), Physiologic, and Consequences


MAT

- Decreased mortality compared to no treatment
- 70% retention in treatment

DATA 2000

- 8 hr course, DEA and SAMHSA registration, X-wavier, maintain a patient log
- Patient totals - 30 for first year, request to increase to 100, maximum 275
- Treatment setting other than "Methadone Clinic"

Buprenorphine



- Partial Opioid Agonist at the Mu-receptor
- High Affinity and Slow dissociation
- Formulation- films, tablets, depot. Patch not approved for MAT
- Phases of treatment
- Dose range - 4-24mg QD or BID
- Duration of treatment - 12-18 months minimal
- Co-prescribe Narcan (Naloxone)

Induction

- Check iStop (PDMP)
- Patient selection - Inpatient vs Outpatient, History, Use patterns, Previous Success
- Urine Drug Screen and COWS - Clinical Opiate Withdrawal Scale
- Location - Office vs Home
- Participated Withdrawal
- Adjunctive Options- Clonidine, Trazodone, Hydroxyzine, Ondansetron, Loperamide, NSAIDs

Maintenance

- Typically, doses stay the same
- Insurance formulary